PMID: 10901475Jul 20, 2000

The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group

Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
Michael Diestelhorst


To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily. In a 6-month, multicenter, randomized, open-label study 242 patients with POAG or OH whose IOP was not controlled with timolol 0.5% b.i.d. were enrolled. Eyes had not been treated with pilocarpine and latanoprost for at least 2 years. An analysis of covariance with diurnal IOP change from baseline to month 6 for study eyes was performed. Four patients on latanoprost 0.005% and 35 on pilocarpine 2% did not complete the study (P<0.001). Two hundred and forty patients were included in the intent-to-treat analysis. For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001). IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes. The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in ...Continue Reading


Sep 3, 2002·Survey of Ophthalmology·R SusannaYoshiaki Kitazawa
Sep 3, 2002·Survey of Ophthalmology·Michael DiestelhorstCarol B Toris
Feb 18, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hiroshi Kobayashi
Jan 31, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hiroshi Kobayashi
Jan 22, 2002·The British Journal of Ophthalmology·Tin AungSteve K L Seah
Apr 3, 2001·Expert Opinion on Investigational Drugs·C Lindén
Feb 22, 2012·Expert Opinion on Pharmacotherapy·Maurizio DigiuniLuca Rossetti
Jan 3, 2014·Chinese Medical Sciences Journal = Chung-kuo I Hsüeh K'o Hsüeh Tsa Chih·Shun-hua Zhang, Jia-liang Zhao
Feb 27, 2001·Current Opinion in Ophthalmology·R Susanna, F A Medeiros
May 30, 2020·Drug Development and Industrial Pharmacy·Girdhari RoyVenkata Vamsi Krishna Venuganti
Aug 30, 2008·Drugs & Aging·Carroll A B WebersJan S A G Schouten

Related Concepts

Adrenergic beta-Antagonists
Antihypertensive Agents
Circadian Rhythms
Drug Administration Schedule
Drug Augmentation
Glaucoma, Open-Angle
Physiologic Intraocular Pressure
Miotic Effect

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.